Taiwan Stock Exchange · Healthcare
Panion & Bf Biotech stock from India: price, numbers and tax
Panion & Bf Biotech (1760) is not currently available to trade on Paasa; this guide covers the price, the numbers and the Indian tax treatment.
By Paasa · Updated
Panion & Bf Biotech at a glance
- Price
- NT$54.60+NT$0.00 (0.00%)
- Market cap
- NT$4.68B
- Day range
- NT$54.30 – NT$54.70
- P/E
- 21.75
- Dividend yield
- 3.66%
- Volume
- 117.06K
- 1 month
- -5.86%
- 6 months
- -14.02%
- YTD
- -13.33%
- 1 year
- -22.55%
- 5 years
- -21.44%
Panion & Bf Biotech statements, FY2021–FY2025
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | NT$2.1B | NT$2.0B | NT$1.9B | NT$2.4B | NT$1.9B |
| Gross profit | NT$1.1B | NT$1.1B | NT$974.4M | NT$1.3B | NT$912.1M |
| Operating income | NT$307.8M | NT$205.7M | NT$156.8M | NT$341.1M | NT$199.4M |
| Net income | NT$190.2M | NT$124.5M | NT$77.2M | NT$182.3M | NT$104.4M |
| Earnings per share | NT$2.22 | NT$1.45 | NT$0.90 | NT$2.13 | NT$1.32 |
| EBITDA | NT$446.3M | NT$405.3M | NT$327.2M | NT$504.6M | NT$343.0M |
| Total assets | NT$3.2B | NT$3.2B | NT$3.2B | NT$3.1B | NT$3.0B |
| Total debt | NT$647.7M | NT$704.9M | NT$727.8M | NT$482.3M | NT$502.6M |
| Cash and short-term investments | NT$460.3M | NT$558.4M | NT$534.6M | NT$464.3M | NT$348.9M |
| Shareholders' equity | NT$2.0B | NT$1.9B | NT$1.9B | NT$2.0B | NT$1.9B |
| Operating cash flow | NT$298.7M | NT$351.2M | NT$177.4M | NT$489.9M | NT$401.2M |
| Free cash flow | NT$150.4M | NT$165.5M | −NT$3.8M | NT$291.2M | NT$231.2M |
| Capital expenditure | −NT$148.3M | −NT$185.7M | −NT$181.2M | −NT$198.6M | −NT$170.0M |
Fiscal years as reported, the latest ending 31 Dec 2025. Figures in TWD; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| Locus Cell | 6891.TWO | $42.45 | $8.51B |
| Savior Lifetec | 4167.TWO | $19.60 | $6.50B |
| Sinphar Pharmaceutical | 1734.TW | NT$32.10 | NT$6.47B |
| TaiGen Biopharmaceuticals | 4157.TWO | $8.73 | $6.21B |
| Orient Pharma | 4166.TWO | $24.75 | $6.02B |
| OBI Pharma | 4174.TWO | $43.10 | $5.67B |
| Formosa Optical Technology | 5312.TWO | $89.50 | $5.38B |
| Mycenax Biotech | 4726.TWO | $23.40 | $4.84B |
Peers as grouped by the data provider. This is not an investment recommendation.
Why invest in Panion & Bf Biotech from India
What Panion & Bf Biotech does
Panion & Bf Biotech Inc. is a biopharmaceutical firm operating in Taiwan, engaged in the production and distribution of a diverse range of pharmaceutical goods. Its offerings cater to several key therapeutic and wellness segments, including medical aesthetics, renal care, respiratory health, and gastrointestinal support. Panion & Bf Biotech operates in the Medical - Pharmaceuticals industry within the Healthcare sector.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
What tax do I pay in India when I sell Panion & Bf Biotech shares?
In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the TWD/INR rate on the day you bought and the day you sold, so the currency move is part of the gain.